Seewann H L, Gastl G, Lang A, Abbrederis K, Thaler J, Flener R, Huber C
III. Medizinische Abteilung, Landeskrankenhaus Graz, Austria.
Blut. 1988 Apr;56(4):161-3. doi: 10.1007/BF00320746.
We investigated the effect of human recombinant DNA-derived IFN-alpha-2 given in a dose of 1-2 X 10(6) units daily by subcutaneous injection to five patients with advanced idiopathic myelofibrosis (IM). Transfusion dependent anemia and symptomatic splenomegaly were taken as inclusion criteria for this pilot study. Two patients succumbed, one and three months after starting interferon-treatment because of pneumonia and traumatic cranial injury, respectively. While on IFN-treatment no improvement of cytopenia or reduction of splenomegaly was seen in four of the patients. In one patient, however, the requirement for erythrocyte transfusions decreased from 5 to 1.7 monthly upon IFN-treatment. After two, four and six months respectively IFN-treatment had to be stopped in these cases because of progressive thrombocytopenia and/or neutropenia. These observations suggest, that IFN-alpha might be of only marginal value in the treatment of advanced idiopathic myelofibrosis.
我们研究了皮下注射剂量为每日1 - 2×10⁶单位的人重组DNA源干扰素α-2对5例晚期特发性骨髓纤维化（IM）患者的影响。本初步研究的纳入标准为输血依赖型贫血和有症状的脾肿大。两名患者分别在开始干扰素治疗1个月和3个月后因肺炎和外伤性颅脑损伤死亡。在接受干扰素治疗期间，4例患者的血细胞减少症未改善，脾肿大也未缩小。然而，1例患者在接受干扰素治疗后，每月红细胞输注需求量从5次降至1.7次。在这些病例中，分别在治疗2个月、4个月和6个月后，由于进行性血小板减少和/或中性粒细胞减少，不得不停止干扰素治疗。这些观察结果表明，干扰素α在晚期特发性骨髓纤维化的治疗中可能仅有微不足道的价值。
